Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer
Authors
Keywords
-
Journal
Pharmaceutics
Volume 15, Issue 4, Pages 1252
Publisher
MDPI AG
Online
2023-04-17
DOI
10.3390/pharmaceutics15041252
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2023
- (2023) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- SnapShot: Cancer chemotherapy
- (2023) Luca Falzone et al. CELL
- Validating chemoimmunotherapy in small-cell lung cancer
- (2022) Katherine E R Smith et al. LANCET ONCOLOGY
- Strategies and End Points in the Development of Novel Immunotherapy Trials for Patients With Unresectable, Locally Advanced Non–Small-Cell Lung Cancer
- (2022) Nathan A. Pennell JOURNAL OF CLINICAL ONCOLOGY
- A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review
- (2022) Robert A. Ramirez et al. Translational Lung Cancer Research
- Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC – an update from the PACIFIC trial
- (2021) Corinne Faivre-Finn et al. Journal of Thoracic Oncology
- First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
- (2021) Luis Paz-Ares et al. LANCET ONCOLOGY
- Properties of FDA-approved small molecule protein kinase inhibitors: a 2021 update
- (2021) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Narrative review: mesenchymal-epithelial transition inhibitors—meeting their target
- (2021) Danish Safi et al. Translational Lung Cancer Research
- Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
- (2021) Julianne D. Twomey et al. AAPS Journal
- Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion
- (2021) Roberto Filippi et al. EXPERT OPINION ON PHARMACOTHERAPY
- Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study
- (2021) Michael Boyer et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS G12C–Mutant Non–Small Cell Lung Cancer
- (2021) Rajwanth Veluswamy et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
- (2021) Diwakar Davar et al. SCIENCE
- Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway
- (2021) Jian Carrot-Zhang et al. Cell Reports
- Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
- (2021) Yanna Lei et al. Frontiers in Oncology
- Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
- (2021) Donghui Wang et al. Frontiers in Oncology
- Lorlatinib Exposure‐Response Analyses for Safety and Efficacy in a Phase 1/2 Trial to Support Benefit–Risk Assessment in Non‐Small Cell Lung Cancer
- (2021) Joseph Chen et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
- (2021) Katsuyuki Hotta et al. International Journal of Clinical Oncology
- Adoptive T Cell Therapy for Solid Tumors: Pathway to Personalized Standard of Care
- (2021) Shuyang S. Qin et al. Cells
- A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review)
- (2021) Luca Falzone et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- (2021) Justin F Gainor et al. LANCET ONCOLOGY
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- KRAS-targeted therapies in advanced solid cancers: drug the undruggable?
- (2021) Khalil Saleh et al. PHARMACOGENOMICS
- Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non–Small Cell Lung Cancer
- (2021) Akhil Kapoor et al. JAMA Oncology
- Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
- (2020) J. Mazieres et al. ANNALS OF ONCOLOGY
- ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment for metastatic non-small cell lung cancer
- (2020) D. Planchard et al. ANNALS OF ONCOLOGY
- Lung Cancer Pathology
- (2020) William D. Travis CLINICS IN CHEST MEDICINE
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
- (2020) David S Hong et al. LANCET ONCOLOGY
- Pharmacophore-based designing of putative ROS-1 targeting agents for NSCLC
- (2020) Disha Pathak et al. MOLECULAR DIVERSITY
- Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
- (2020) Alexander Drilon et al. NATURE MEDICINE
- Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
- (2020) Louis Buscail et al. Nature Reviews Gastroenterology & Hepatology
- Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy
- (2020) Ufuk Degirmenci et al. Cells
- Strophanthidin Attenuates MAPK, PI3K/AKT/mTOR, and Wnt/β-Catenin Signaling Pathways in Human Cancers
- (2020) Dhanasekhar Reddy et al. Frontiers in Oncology
- Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation
- (2020) SHUNSAKU MIYAUCHI et al. ANTICANCER RESEARCH
- Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis
- (2020) Xiaoxiang Zhou et al. BMC Medicine
- Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
- (2020) Lingzhi Hong et al. Journal of Thoracic Oncology
- Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- (2020) Paul K. Paik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer
- (2020) Naiyer A. Rizvi et al. JAMA Oncology
- Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
- (2020) Keisuke Onoi et al. Journal of Clinical Medicine
- Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
- (2020) Raju K. Vaddepally et al. Cancers
- Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
- (2020) Koichi Ando et al. Cancers
- The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping
- (2020) Ravi Salgia et al. CANCER TREATMENT REVIEWS
- Capmatinib: First Approval
- (2020) Sohita Dhillon DRUGS
- Genetic Markers in Lung Cancer Diagnosis: A Review
- (2020) Katarzyna Wadowska et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
- (2020) Hossein Borghaei et al. CANCER
- KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
- (2020) P.A. Jänne et al. EUROPEAN JOURNAL OF CANCER
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer
- (2020) Jürgen Wolf et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- (2020) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The human microbiome in the 21st century
- (2020) Elze Rackaityte et al. Nature Communications
- Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
- (2020) Willemijn S M E Theelen et al. Lancet Respiratory Medicine
- Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
- (2020) James Welsh et al. Journal for ImmunoTherapy of Cancer
- Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
- (2020) Rilan Bai et al. Biomarker Research
- FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid cancers with RET Gene Mutations or Fusions
- (2020) Diana Bradford et al. CLINICAL CANCER RESEARCH
- Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2020) Tony S. Mok et al. DRUGS
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
- (2020) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Microbiome: A Supportive or a Leading Actor in Lung Cancer?
- (2020) Diana Martins et al. PATHOBIOLOGY
- Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
- (2020) Erez N. Baruch et al. SCIENCE
- The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
- (2020) Valerio Gristina et al. Pharmaceuticals
- NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors
- (2020) Romel Somwar et al. Communications Biology
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
- (2019) Koutaroh Okada et al. EBioMedicine
- Gut Microbiota and Cancer: From Pathogenesis to Therapy
- (2019) Silvia Vivarelli et al. Cancers
- ALK Inhibitors in the Treatment of ALK Positive NSCLC
- (2019) Muhammad Khan et al. Frontiers in Oncology
- Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients
- (2019) Sarabjot Pabla et al. Journal for ImmunoTherapy of Cancer
- Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial
- (2019) Yi-Long Wu et al. Journal of Thoracic Oncology
- K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
- (2019) Huizhong Feng et al. BIOCHEMISTRY
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
- (2019) Tony S K Mok et al. LANCET
- Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
- (2019) Corey J. Langer et al. Journal of Thoracic Oncology
- Cell type-dependent differential activation of ERK by oncogenic KRAS in colon cancer and intestinal epithelium
- (2019) Raphael Brandt et al. Nature Communications
- Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
- (2019) Xiangfeng Shen et al. Frontiers in Immunology
- Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer
- (2019) Willemijn S. M. E. Theelen et al. JAMA Oncology
- The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients
- (2019) Quan Lin et al. Journal of Translational Medicine
- A Phase 2 Study of Lenvatinib in Patients With RET Fusion-Positive Lung Adenocarcinoma
- (2019) Toyoaki Hida et al. LUNG CANCER
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- The dark side of immunotherapy: challenges facing the new hope in cancer treatment
- (2019) Eduard Teixidor et al. Annals of Translational Medicine
- Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial
- (2019) D Moro-Sibilot et al. ANNALS OF ONCOLOGY
- REToma: a cancer subtype with a shared driver oncogene
- (2019) Takashi Kohno et al. CARCINOGENESIS
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
- (2019) Yukio Hosomi et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort
- (2019) Neal E. Ready et al. Journal of Thoracic Oncology
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
- (2019) Jhanelle E. Gray et al. Journal of Thoracic Oncology
- OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
- (2019) M. Garassino et al. Journal of Thoracic Oncology
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- (2019) Luis Paz-Ares et al. LANCET
- Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
- (2019) Carmine Carbone et al. MEDIATORS OF INFLAMMATION
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Comparative Analysis of Individual RAS Mutations in Cancer Biology
- (2019) Carmen Muñoz-Maldonado et al. Frontiers in Oncology
- Targeting innate sensing in the tumor microenvironment to improve immunotherapy
- (2019) Zhida Liu et al. Cellular & Molecular Immunology
- Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
- (2019) Liwen Xiong et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials
- (2019) Alexander Drilon et al. LANCET ONCOLOGY
- Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
- (2019) Robert C Doebele et al. LANCET ONCOLOGY
- Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer
- (2019) Kazuhiko Nakagawa et al. LUNG CANCER
- Pathology and genetics of anaplastic large cell lymphoma
- (2019) Vasiliki Leventaki et al. SEMINARS IN DIAGNOSTIC PATHOLOGY
- Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
- (2018) E E Vokes et al. ANNALS OF ONCOLOGY
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy
- (2018) Enriqueta Felip et al. Clinical Lung Cancer
- Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non–Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study
- (2018) Hounai Xie et al. Clinical Lung Cancer
- Alectinib: A Review in Advanced, ALK-Positive NSCLC
- (2018) Julia Paik et al. DRUGS
- Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
- (2018) Jessica J. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
- (2018) Tony S. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
- (2018) Gregory P. Kalemkerian et al. JOURNAL OF CLINICAL ONCOLOGY
- Brief Report: Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients with RET -Rearranged Lung Cancers
- (2018) Alexander Drilon et al. Journal of Thoracic Oncology
- Clinical and Translational Implications of RET Rearrangements in Non–Small Cell Lung Cancer
- (2018) Roberto Ferrara et al. Journal of Thoracic Oncology
- KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
- (2018) Irene Ferrer et al. LUNG CANCER
- Mechanisms of receptor tyrosine kinase activation in cancer
- (2018) Zhenfang Du et al. Molecular Cancer
- The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
- (2018) Brandon Golding et al. Molecular Cancer
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
- (2018) Matthew Dankner et al. ONCOGENE
- Heterogeneity in Lung Cancer
- (2018) Vitor Manuel Leitão de Sousa et al. PATHOBIOLOGY
- Dendritic Cell-Based Immunotherapy for Solid Tumors
- (2018) Nam-Chul Jung et al. Translational Oncology
- EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
- (2018) Hongyang Lu et al. OncoTargets and Therapy
- Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
- (2018) Satoshi Yoda et al. Cancer Discovery
- Delivery Strategies for Immune Checkpoint Blockade
- (2018) Qian Chen et al. Advanced Healthcare Materials
- Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
- (2018) Youjin Kim et al. Cancer Research and Treatment
- Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy
- (2018) Thomas C Weart et al. Cancer Management and Research
- Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report
- (2018) Zhang Ling et al. Cancer Biology & Medicine
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Co-mutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade
- (2018) Jie Wang et al. CANCER RESEARCH
- Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
- (2018) Yi-Long Wu et al. Journal of Thoracic Oncology
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
- (2018) Fabrice Barlesi et al. LANCET ONCOLOGY
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- (2018) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
- (2018) D. Ross Camidge et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The hallmarks of successful anticancer immunotherapy
- (2018) Lorenzo Galluzzi et al. Science Translational Medicine
- Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data
- (2018) Junlong Li et al. BMJ Open
- Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
- (2018) Sung Won Lim et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer
- (2018) Karen Reckamp et al. CURRENT MEDICAL RESEARCH AND OPINION
- Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
- (2018) Benjamin J Solomon et al. LANCET ONCOLOGY
- NTRK fusion-positive cancers and TRK inhibitor therapy
- (2018) Emiliano Cocco et al. Nature Reviews Clinical Oncology
- Spectrum of Lung Adenocarcinoma
- (2018) Barry D. Hutchinson et al. SEMINARS IN ULTRASOUND CT AND MRI
- Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
- (2017) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
- (2017) Sun Min Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
- (2017) Alexis B. Cortot et al. JNCI-Journal of the National Cancer Institute
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
- (2017) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Recent Advances in Targeting ROS1 in Lung Cancer
- (2017) Jessica J. Lin et al. Journal of Thoracic Oncology
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
- (2017) Jean-Charles Soria et al. LANCET
- Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
- (2017) Toyoaki Hida et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Dabrafenib plus trametinib in patients with previously untreated BRAF V600E -mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
- (2017) David Planchard et al. LANCET ONCOLOGY
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable
- (2017) Thanyanan Reungwetwattana et al. LUNG CANCER
- Mechanisms of Resistance to NTRK Inhibitors and Therapeutic Strategies in NTRK1-Rearranged Cancers
- (2017) Miho J. Fuse et al. MOLECULAR CANCER THERAPEUTICS
- FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond
- (2017) Lee Pai‐Scherf et al. ONCOLOGIST
- Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
- (2017) Alexis B. Cortot et al. JNCI-Journal of the National Cancer Institute
- Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival
- (2017) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer andBRAFmutation
- (2017) Xi Ding et al. Cancer Medicine
- Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
- (2017) Kiyotaka Yoh et al. Lancet Respiratory Medicine
- Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
- (2017) Pilar Garrido et al. Therapeutic Advances in Medical Oncology
- A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
- (2017) Patricia Gaule et al. JAMA Oncology
- ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice
- (2017) Paul Hofman Cancers
- EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients
- (2017) et al. Cancers
- Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
- (2017) et al. Cancers
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
- (2016) J. M. Kim et al. ANNALS OF ONCOLOGY
- Risk factors for lung cancer worldwide
- (2016) Jyoti Malhotra et al. EUROPEAN RESPIRATORY JOURNAL
- Immune checkpoint inhibitors in lung cancer: past, present and future
- (2016) Nagashree Seetharamu et al. Future Oncology
- Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer
- (2016) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis
- (2016) Disha Pathak et al. JOURNAL OF MOLECULAR GRAPHICS & MODELLING
- Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC
- (2016) Edurne Arriola et al. Journal of Thoracic Oncology
- Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations
- (2016) Alexa B. Schrock et al. Journal of Thoracic Oncology
- First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
- (2016) Martin Schuler et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Cabozantinib in patients with advanced RET -rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
- (2016) Alexander Drilon et al. LANCET ONCOLOGY
- Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
- (2016) David Planchard et al. LANCET ONCOLOGY
- Occupational exposure to carcinogens: Benzene, pesticides and fibers
- (2016) Luca Falzone et al. Molecular Medicine Reports
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis
- (2016) Jung-Soo Pyo et al. PATHOLOGY RESEARCH AND PRACTICE
- BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis
- (2016) Soo Kyung Nam et al. PLoS One
- Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinaseBRAF-mutant lung cancer
- (2016) Ross A. Okimoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Facteurs de risque professionnels du cancer bronchopulmonaire
- (2016) F. Delva et al. REVUE DES MALADIES RESPIRATOIRES
- Classification and Pathology of Lung Cancer
- (2016) Min Zheng Surgical Oncology Clinics of North America
- Tremelimumab: research and clinical development
- (2016) Francisco Javier Ibarrondo et al. OncoTargets and Therapy
- Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2016) J. F. Gainor et al. Cancer Discovery
- PD-1 and its ligands are important immune checkpoints in cancer
- (2016) Yinan Dong et al. Oncotarget
- The RAS-RAL axis in cancer: evidence for mutation-specific selectivity in non-small cell lung cancer
- (2015) Sunny Guin et al. ACTA PHARMACOLOGICA SINICA
- Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
- (2015) M. Schuler et al. ANNALS OF ONCOLOGY
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene of the month:MET
- (2015) Garret Skead et al. JOURNAL OF CLINICAL PATHOLOGY
- Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer
- (2015) Johan F. Vansteenkiste et al. Journal of Thoracic Oncology
- The 2015 World Health Organization Classification of Lung Tumors
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart
- (2015) William D. Travis et al. Journal of Thoracic Oncology
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
- (2015) Helen Y. Zou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors
- (2015) Monika A. Davare et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring MET Mutations Causing Exon 14 Skipping
- (2015) P. K. Paik et al. Cancer Discovery
- Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
- (2015) G. M. Frampton et al. Cancer Discovery
- Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities
- (2015) F. Skoulidis et al. Cancer Discovery
- Non-small-cell lung cancer
- (2015) Cesare Gridelli et al. Nature Reviews Disease Primers
- PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
- (2015) Matthias Scheffler et al. Oncotarget
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
- (2014) S Li et al. BRITISH JOURNAL OF CANCER
- Small cell lung cancer: Where do we go from here?
- (2014) Lauren Averett Byers et al. CANCER
- Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboringBRAFmutations in the Lung Cancer Mutation Consortium
- (2014) Liza C. Villaruz et al. CANCER
- Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
- (2014) Anya M. Litvak et al. Journal of Thoracic Oncology
- Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
- (2014) LANCET
- Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
- (2014) J.L. Kuiper et al. LUNG CANCER
- Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
- (2014) D. Kazandjian et al. ONCOLOGIST
- Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure
- (2014) SAVERIO CANDIDO et al. ONCOLOGY REPORTS
- Prognostic Value of MET Gene Copy Number and Protein Expression in Patients with Surgically Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Published Literatures
- (2014) Baoping Guo et al. PLoS One
- ROS1-Rearranged Lung Cancer
- (2013) Akihiko Yoshida et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Cetuximab Response of Lung Cancer-Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization
- (2013) J. Cho et al. CANCER RESEARCH
- Molecular Pathways: ROS1 Fusion Proteins in Cancer
- (2013) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
- (2013) John R. Goffin et al. CLINICAL THERAPEUTICS
- Targeting the MET gene for the treatment of non-small-cell lung cancer
- (2013) F. Gelsomino et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Subtyping Non–Small Cell Lung Cancer
- (2013) Giulio Rossi et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials
- (2013) William D. Travis et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
- (2013) J. Jean Cui JOURNAL OF MEDICINAL CHEMISTRY
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Identifying and Targeting ROS1 Gene Fusions in Non-Small Cell Lung Cancer
- (2012) K. D. Davies et al. CLINICAL CANCER RESEARCH
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- RETFusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer
- (2012) Rui Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Increasing Lung Cancer Death Rates Among Young Women in Southern and Midwestern States
- (2012) Ahmedin Jemal et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- (2012) R. Katayama et al. Science Translational Medicine
- The genetics and biology of KRAS in lung cancer
- (2012) Peter M. K. Westcott et al. Chinese Journal of Cancer
- Role and Relevance of TrkB Mutations and Expression in Non-Small Cell Lung Cancer
- (2011) T. Harada et al. CLINICAL CANCER RESEARCH
- History of Small-Cell Lung Cancer
- (2011) Shadi Haddadin et al. Clinical Lung Cancer
- Lung Cancer: Epidemiology, Etiology, and Prevention
- (2011) Charles S. Dela Cruz et al. CLINICS IN CHEST MEDICINE
- The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC: Figure 1
- (2011) Kathy Gately et al. JOURNAL OF CLINICAL PATHOLOGY
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- (2011) William D. Travis et al. Journal of Thoracic Oncology
- Small-cell lung cancer
- (2011) Jan P van Meerbeeck et al. LANCET
- Classification of Lung Cancer
- (2011) William D. Travis SEMINARS IN ROENTGENOLOGY
- Exon scanning by reverse transcriptase–polymerase chain reaction for detection of known and novel EML4–ALK fusion variants in non–small cell lung cancer
- (2011) Heather R. Sanders et al. Cancer Genetics
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines
- (2009) Jeet Gandhi et al. PLoS One
- Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung
- (2008) Antonio Marchetti et al. HUMAN MUTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation